Salus Medical Completes Series A+ Financing Led by Fosun Pharma to Accelerate Global Expansion

VCBeat has learned that, recently,Shenzhen Salus Medical Technology Co., Ltd. (hereinafter referred to as “Salus”) announced the completion of its Series A+ financing round.This round of financing was led by leading enterprises in the healthcare industryFosun Pharmaceutical led the investment, Changzhou Weichi Investment followed, and existing shareholder SCGC continued to increase its investment.. This round of funding will be primarily allocated to the regulatory registration and filing, capacity expansion, and global market development of its fully domestic sequencing platform, further consolidating its position as an innovation leader in the life sciences tools sector.

In January 2025, the Salus Pro sequencer, independently developed by Salus Medical, obtained the Class III medical device registration certificate from the National Medical Products Administration (NMPA). It became the first domestically produced equipment in China to achieve full-scenario coverage based on reversible terminator sequencing technology, providing an optimal domestic alternative following the ban on Illumina. The company adheres to“Technological Self-Reliance + Industrial Closed Loop”as the core, has been establishedA full-chain R&D system covering optics, fluidics, chips, and reagents to build a fully domesticated sequencing and super-resolution spatial omics platform, with over 100 authorized patents, its products span the fields of scientific research, clinical practice, and agriculture, committing to becoming a global leader in life science tools.

This round marks another significant milestone for Salus, following its Series A financing and the regulatory approval of Salus Pro. Further collaboration with leading industrial investors in the healthcare sector will continue to enhance Salus’s R&D capabilities and global commercialization capacity.

This financing marksFosun Pharmaceutical and Salus Enter a New Phase of "Mutual Empowerment" in Strategic PartnershipIn this new phase, both parties will continue to engage in deep collaboration centered on product R&D, integration of industrial chain resources, and global market expansion, jointly driving technological breakthroughs and market penetration for domestically produced high-end medical equipment. Both parties will"Innovation-Driven"as the core strategy, accelerate the development of innovative technologies and products that meet clinical needs, and create higher-quality Chinese solutions.

Salus, founded in 2020, is a National High-Tech Enterprise and a National Specialized and Sophisticated “Little Giant” Enterprise. It focuses on developing upstream sequencing platforms with independent intellectual property rights and has built a globally leading super-resolution spatial omics platform based on these technologies, enabling the independent development of genomic and spatial omics products as well as their translation into research and clinical applications. The company has overcome previous bottlenecks in throughput, cost, resolution, and automation associated with sequencing and omics products, and has obtained multiple key certifications, including the Class III Medical Device Registration Certificate from China’s National Medical Products Administration (NMPA) and the EU CE-IVDR mark. With rapid growth, Salus now possesses internationally leading sequencing and omics platforms, providing comprehensive solutions for mid- and downstream applications, with its products selling well both domestically and overseas.